Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyunah | - |
dc.contributor.author | Lee, Seung-Hwan | - |
dc.contributor.author | Cho, Jae-Hyoung | - |
dc.contributor.author | Lee, Hyunyong | - |
dc.contributor.author | Yim, Hyeon Woo | - |
dc.contributor.author | Yoon, Kun-Ho | - |
dc.contributor.author | Kim, Hun-Sung | - |
dc.date.available | 2021-02-22T04:57:25Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0269-4727 | - |
dc.identifier.issn | 1365-2710 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/1017 | - |
dc.description.abstract | What is known and objectives Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel antidiabetic agents that have advantages of weight loss and prevention of cardiovascular diseases. However, SGLT2i have various side effects. To understand their effectiveness, we analysed patients who had discontinued the use of dapagliflozin, an SGLT2i, 3 months after the initial prescription. We evaluated the discontinuation rate of dapagliflozin and the incidence rate of its side effects. Methods Patients who were initially prescribed dapagliflozin for blood sugar control from December 2014 to December 2016 were analysed. Data of patients in whom dapagliflozin administration was discontinued 90 days after initial prescription were collected separately, and the reasons were evaluated by a direct chart review. Results and discussion A total of 8.96% (149/1663) patients discontinued dapagliflozin or switched medications within 3 months. Dapagliflozin was discontinued in 24.8% (37/149) of cases due to unexpected causes such as increased blood sugar and weight gain. The patients who discontinued dapagliflozin use due to side effects comprised 49.7% (74/149). Two major side effects were genital tract infection in women (P < .001 compared with men) and urinary tract infection, which increased with age (P = .030). Malpractice of medical personnel, insurance problems or causes of termination not related to dapagliflozin use comprised 14.1% (21/149). What is new and conclusion The incidence of side effects with dapagliflozin was not as high as expected. Physicians should consider instructions prior to prescribing dapagliflozin so that its discontinuation would decrease considerably. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/jcpt.13205 | - |
dc.identifier.scopusid | 2-s2.0-85086329758 | - |
dc.identifier.wosid | 000539823500001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.45, no.6, pp 1271 - 1277 | - |
dc.citation.title | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.volume | 45 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1271 | - |
dc.citation.endPage | 1277 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INADEQUATE GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordPlus | SGLT2 INHIBITORS | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | TYPE-2 | - |
dc.subject.keywordPlus | DAPAGLIFLOZIN | - |
dc.subject.keywordPlus | EMPAGLIFLOZIN | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | dapagliflozin | - |
dc.subject.keywordAuthor | real-world data | - |
dc.subject.keywordAuthor | real-world evidence | - |
dc.subject.keywordAuthor | SGLT2i | - |
dc.subject.keywordAuthor | side effects | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13205 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.